Clinical Trial Search

Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…

Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001

Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale

Primary: Subjective Opioid Withdrawal Scale Score (SOWS) — 16; 4; 24 units on a scale

Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale

Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events

Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…

Primary: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour — 9; 19 Participants

Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…

Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change

Primary: Peak SOWS Scores at Baseline and Over Time — 3.6; 5.2; 6.0; 4.7 score on a scale

Primary: Successful Vivitrol Induction — 10 Participants

Primary: Finnegan Neonatal Abstinence Scoring System — 7.5; 8.5; 6.6; 5.7 scores on a scale

Primary: Buprenorphine Pharmacokinetics

Primary: Abuse Liability as Assessed by Visual Analogue Scale — 23.9; 20.9; 22.8 score on a scale*days — p=.950

Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours

Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42

Primary: Subjective Opioid Withdrawal Scale-Gossop (SOWS) Scale Score — 7.0; 9.1 score on a scale — p=.05

Primary: Illicit Opioid Use as Determine by Urine Dipsticks — 13.64; 32.56 % of urines positive for opioids — p=0.035

Primary: Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores — 7.8; 7.6; 9.4; 10.2 score on a scale — p=0.0166

Primary: Participant Acceptability of the Interventions — 1; 0 Participants

Primary: Percentage of Patients Who Tolerate Buprenorphine Initiation — 27 Participants

Primary: Days of Treatment With Opioid Medication — 13.9; 22.9 days

Primary: Pain Perception Measured Using the Cold-pressor Test (CPT) — 24.01; 42.02 seconds

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Change in Salivary Progesterone Level — 237.86; 97.87 pg/ml

Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale

Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097